Plain-English translation of NCT05861050 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing whether —a newer type of cancer-fighting drug—works well when combined with three other medications (, , and ) for people with newly diagnosed mantle cell lymphoma who have high-risk features. Researchers want to see if this medication combination can help people stay cancer-free for longer and how safe the treatment is overall.
Mantle cell lymphoma is an aggressive blood cancer that can be hard to treat, especially when it has high-risk features. This trial exists to find out whether combining this newer medication with established treatments might be more effective than standard approaches.
You likely qualify if…
You likely don't qualify if…
You would receive the four medications through a combination of pill form and infusions into your veins, following a treatment schedule determined by the study team. Throughout the study, you would have regular visits for blood tests, bone marrow biopsies, and imaging scans (CT or PET) to check how well the treatment is working and monitor for side effects. The study will follow you for at least 24 months to see how long you stay cancer-free.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
United States